• Continuing effectiveness of serogroup a meningococcal conjugate vaccine, Chad, 2013

      Gamougam, K; Daugla, D M; Toralta, J; Ngadoua, C; Fermon, F; Page, A-L; Djingarey, M H; Caugant, D A; Manigart, O; Trotter, C L; et al. (Center for Disease Control, 2015-01-01)
      In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated areas, but an epidemic continued in the rest of Chad. In 2012, the remaining Chad population was vaccinated, and the epidemic was halted.
    • Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial

      Daugla, D M; Gami, J P; Gamougam, K; Naibei, N; Mbainadji, L; Narbé, M; Toralta, J; Kodbesse, B; Ngadoua, C; Coldiron, M E; et al. (Elsevier, 2013-09-11)
      A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
    • Use of Vibrio cholerae Vaccine in an Outbreak in Guinea

      Luquero, F J; Grout, L; Ciglenecki, I; Sakoba, K; Traore, B; Heile, M; Diallo, A A; Itama, C; Page, A-L; Quilici, M-L; et al. (Massachusetts Medical Society, 2014-05-29)